-
19-08-2017, 12:57 PM
#121
I'm out of this one but worth keeping an eye on if they can get a few more channels going (ie Australia / Dogs). Even if not it might be worth a look sub 3c. Too much growth priced in for me right now though.
Felix, qui potest rerum cognoscere causas
-
29-08-2017, 04:20 PM
#122
Report to 30 June published today. Australian launch of Arthrem a bit slower than expected but now scheduled for late September. NSW only to start with. PIL now have experience with advertising and distribution in NZ and the impact on sales (good). Assume they will follow the same path in NSW.
Launch of Artevite for dogs in NZ now also scheduled for late September. Turning the corner?
-
29-08-2017, 09:56 PM
#123
Member
Yes. Just saw this announcement. This is very encouraging. This combined with a new CEO should create some serious growth by year end.
-
28-09-2017, 08:53 AM
#124
Member
INTERIM: PIL: Promisia appoints new Chief Executive
The directors of Promisia Integrative are pleased to report on the six months
to 30 June 2017 for the company and its subsidiaries. The period under
review has required a sharp refocusing of management effort to secure the
launch of Arthrem in Australia and the launch of Artevite in New Zealand.
Financial Results
Sales for the period were $1,318,000, a 33% increase over the same period in
the previous year. The operating net loss for the period was $349, 000, a
slight reduction on the 2016 result for the same period.
New Zealand Sales
Sales of Arthrem have stabilised and the market may have reached a point
where the rapid growth seen in 2016 has abated. The company believes that
market growth is available but at a slower rate than experienced in the past.
Competitive products have appeared, as expected, but their presence is
expected to grow the overall market. As a brand, Arthrem is well recognised
and continued to be the best selling over the counter item in pharmacies in
dollar terms. The company continues to work with its distributor to maximise
sales to pharmacies and has produced a package of instore support material
for pharmacies.
The company's online presence has been enhanced with an excellent response
level on Facebook. Positive customer testimonials are received regularly and
the level of online awareness and sales is increasing.
Australia
The directors are pleased to advise that the company has entered into a
pharmacy distribution agreement with Pharmabroker Sales Pty Ltd, a leading
wholesaler of a wide range of products to pharmacies across Australia. The
initial focus will be solely on New South Wales which has a higher percentage
of independent pharmacies rather than franchises or members of national
chains. Pharmabroker has been of considerable assistance to the company in
securing business relationships with other parties required for a successful
launch into this market.
The launch of Arthrem into the Australian market has taken longer than
anticipated. The company's strategy is based on using third parties to
provide services for either all or specific stages of the marketing chain.
It has taken much longer than expected to complete satisfactory arrangements.
The company is negotiating arrangements for the provision of order fulfilment
and debtor management services in Australia.
Pharmabroker will start marketing Arthrem to pharmacies from the beginning of
October 2017.
Canine Product
The company's product for the treatment of osteoarthritis in dogs is due for
release in late September 2017. The product is to be branded as Artevite and
will be sold through veterinary clinics, pet stores and online. The company
has signed a marketing and distribution agreement with Brooklands Pet
Products of New Plymouth which has an extensive countrywide marketing and
distribution network.
New Markets
The company continues to investigate other markets for Arthrem and one Asian
market is under active investigation with identification of import
requirements and securing regulatory approval being the focus of attention.
Recruitment of new Chief Executive
The directors of Promisia Integrative Ltd are pleased to announce the
appointment of Mr. Rene de Wit as the company's new Chief Executive.
Rene de Wit is an accomplished CEO and change manager with 25 years'
experience in FMCG, food manufacturing, printing, packaging, import/export,
financial services and logistics. He has been particularly successful in
leading and developing teams that deliver. His former roles include CEO or
General Manager positions with Watson & Son, Colorite Group, and Scalzo Food
Industries.
Rene holds a Master of Organic Chemistry and a MBA from the University of
Otago and will take up his position on 9 October 2017.
In the interim, the role of Acting Managing Director has been filled by
director Tom Brankin. The directors thank him for his commitment to the
company over the last six months.
For further information please contact:
Mr Stephen Underwood, Chairman on 027 499 3387
Mr Tom Brankin, Acting Managing Director on 021 944740
End CA:00307914 For:PIL Type:INTERIM Time:2017-09-28 09:40:32
-
16-10-2017, 06:04 PM
#125
To me this is going through some standard operational delays for a small company. Nothing unexpected 'yet'. Price starting to look attractive again. Anyone else still have this on their radar?
Felix, qui potest rerum cognoscere causas
-
16-10-2017, 06:46 PM
#126
Member
Hi FG - I am new to this one, picked it up at 2.8c. Have you been in this one for long?
-
16-10-2017, 07:47 PM
#127
Originally Posted by FarmerGeorge
To me this is going through some standard operational delays for a small company. Nothing unexpected 'yet'. Price starting to look attractive again. Anyone else still have this on their radar?
Competitor offering exactly the same product - Twice the strength, same price as Arthrem. Currently available on special - 3 for price of 2!
Only one way for PIL's revenues and margins to go.
-
16-10-2017, 08:04 PM
#128
Member
Originally Posted by Balance
Competitor offering exactly the same product - Twice the strength, same price as Arthrem. Currently available on special - 3 for price of 2!
Only one way for PIL's revenues and margins to go.
Not sure that's correct
Go Healthy label says its best if you take it with two of their other products
That's kinda cute marketing don't cha think?
-
16-10-2017, 09:17 PM
#129
Originally Posted by Lola
Not sure that's correct
Go Healthy label says its best if you take it with two of their other products
That's kinda cute marketing don't cha think?
Good friend of mine took Arthrem but his chemist recommended he switched over to Go Arthri-Remedy as exactly same product but stronger and cheaper. Chemist said not to worry about the other two products.
Arthrem is being discounted to match the competition and it is possible to get the 60 cap at $29.95 - way down on price of $45 last year.
Not saying one is better than the other - purely an observation of what's happening.
Arthrem has no IP or patent protection.
Both exChairman and CEO resigned, siting time to do other things. Anyone want to hazard a guess as to whether they have been selling down their shareholdings (and as non staff or director, no more SSH required)?
Last edited by Balance; 16-10-2017 at 09:36 PM.
-
17-10-2017, 08:05 PM
#130
Originally Posted by Clints
Hi FG - I am new to this one, picked it up at 2.8c. Have you been in this one for long?
Not currently holding Clint - just an observation that the price is looking much cheaper. Though in my mind at least a lot hangs on the execution of the Australian / pet product sales.
Felix, qui potest rerum cognoscere causas
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks